<DOC>
	<DOCNO>NCT00615602</DOCNO>
	<brief_summary>This trial compare 6 versus 12 month trastuzumab combination dose dense docetaxel follow FE75C adjuvant chemotherapy woman axillary lymph node positive breast cancer overexpressing HER2</brief_summary>
	<brief_title>Six vs 12 Months Trastuzumab With Docetaxel Following FEC Adjuvant Treatment N+ Breast Cancer</brief_title>
	<detailed_description>Anthracycline-containing regimen recommend adjuvant treatment woman node positive breast cancer . In least three large randomize clinical trial addition sequential administration taxane ( paclitaxel docetaxel ) antracycline-based regimen result superior clinical outcome woman node positive early breast cancer . In two large randomize study dose dense administration G-CSF support anthracycline-based paclitaxel combination superior regimen administer every three week without growth factor adjuvant therapy woman axillary node positive breast cancer . In one randomized trial , docetaxel prove superior paclitaxel woman metastatic breast cancer . Trastuzumab ( anti-HER2 monoclonal antibody ) combination paclitaxel superior paclitaxel alone woman metastatic breast cancer overexpressing HER2</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Women histologicallyconfirmed unilateral invasive ductal lobular breast adenocarcinoma HER2/cneu expression document either immunohistochemistry ( score 3+ ) FISH/CISH positivity . A score 2+ immunohistochemistry acceptable FISH/CISH positive Within 60 day surgical excision primary tumor tumorfree operation margin ; least 10 axillary lymph node remove . Tumor involvement least one axillary lymph node ( N0 HER2/cneu expression also eligible ) Absence clinical radiological evidence local metastatic disease Premenopausal postmenopausal woman age 1875 year old Adequate bone marrow function ( absolute neutrophil count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , hemoglobin &gt; 10gr/mm3 ) Adequate liver ( bilirubin &lt; 1.0 time upper limit normal SGOT/SGPT &lt; 2.5 time upper limit normal ) renal function ( creatinine &lt; 1.5mg/dl ) Adequate cardiac function ( LVEF &gt; 50 % ) . Normal electrocardiogram absence significant heart disease Written inform consent Positive pregnancy test . Psychiatric illness social situation would preclude study compliance . Other concurrent uncontrolled illness . Prior concurrent antineoplastic therapy e.g . hormonal therapy , radiation therapy , chemotherapy , biological agent . Previous history invasive malignancy nonmelanomatous skin cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Early breast cancer</keyword>
	<keyword>Axillary node positive</keyword>
	<keyword>HER2 overexpression</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Dose dense</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>FEC</keyword>
</DOC>